A meta-analysis based on propensity analysis studies comparing neoadjuvant immunochemotherapy and neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma.

ABSTRACT:

Background

To systematically compare the efficacy and safety of neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT) in the treatment of resectable esophageal squamous cell carcinoma (ESCC).

Methods

Databases were searched to collect clinical studies comparing NICT and NCRT for ESCC based on propensity score analysis. Primary outcomes included overall survival (OS), disease-free survival (DFS), pathological response rate, local recurrence and distant relapse rate. Secondary outcomes included the number of lymph nodes dissected, R0 resection rate, and postoperative complication rates.

Results

11 studies involving 4,684 patients were included. The NICT group showed significantly better OS and DFS than the NCRT group (HR = 0.61, 95% CI: 0.52-0.7

SUBMITTER: Jin Z 

PROVIDER: S-EPMC12508355 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature